Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-CEA designer T cells
- Development stage
- Phase 1
- Lead developer
- Roger Williams Medical Center
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies, Gene Therapies
- Administration
- Intravenous, Intrahepatic
01
Overview
Anti-CEA designer T cells are second-generation chimeric antigen receptor (CAR) T cells engineered to target cancers expressing carcinoembryonic antigen (CEA). These autologous T cells are genetically modified using mammalian expression vectors to express a "Tandem" chimeric immune receptor (CIR), designated as IgCD28TCR. This construct consists of a single-chain antibody fragment (sFv) specific for CEA fused to the CD28 costimulatory signaling domain and the CD3-zeta (TCR zeta) signaling chain. By incorporating both Signal 1 (activation) and Signal 2 (costimulation), these modified T cells are designed to resist activation-induced cell death (AICD), enhance cytokine secretion (such as IL-2 and IFN-gamma), and promote sustained proliferation upon tumor contact. Clinical trials have investigated these cells for various CEA-positive malignancies, including colorectal, gastric, breast, and lung cancers, utilizing both systemic intravenous administration and regional delivery methods like intrahepatic arterial infusion for liver metastases.
- Other names
- 2nd generation anti-CEA designer T cellsanti-CEA CAR-T cellsanti-CEA immunoglobulin-T-cell receptor-modified T cellsTandem anti-CEA T cells
Beyond the preview
Go deeper on anti-CEA designer T cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-CEA designer T cells.